In 2024, the FDA approved 19 biosimilars across various therapeutic areas, including the first biosimilars for ustekinumab ...

About 43% of patients with sarcoidosis received treatment within 1 year of diagnosis, according to study findings published in Chest. Researchers evaluated treatment rates, treatm ...

AbbVie (ABBV) continues to dominate the adalimumab market with 72% share in the U.S., despite biosimilar threats gaining ground. Read more here.

A study from Spain found a subcutaneous tocilizumab biosimilar to be cost-effective when treating patients with rheumatoid ...

AbbVie executives said they have high hopes for Skyrizi and Rinvoq in the inflammatory bowel disease market after Humira ...

USA: A recent post hoc analysis of two randomized clinical trials has provided insight into the role of C-reactive protein ...

The sequence of biologic treatments in patients with inflammatory bowel disease significantly affects their risk of adverse ...

J&J will protect the branded anti-interleukin (IL)-12/23 biologic Stelara against sales erosion from biosimilars.